Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7795068 multiple-dose study on gastric emptying and oral contraceptive pharmacokinetics
NL-OMON61125Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- May 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of zilebesiran, sponsored by Roche. Started May 2026; status: active, not recruiting.
02
Drugs
zilebesiran
Beyond the preview
Go deeper on NL-OMON61125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61125.